常山药业(300255) - 2020 Q1 - 季度财报

Financial Performance - Total revenue for Q1 2020 was ¥398,337,913.55, a decrease of 13.17% compared to ¥458,732,011.25 in the same period last year[8] - Net profit attributable to shareholders was ¥48,781,306.45, down 13.90% from ¥56,655,872.70 year-on-year[8] - Basic earnings per share decreased by 16.67% to ¥0.05 from ¥0.06 in the same period last year[8] - The company achieved operating revenue of 398.34 million yuan in the first quarter, a decrease of 13.17% compared to the same period last year[26] - Net profit attributable to shareholders was 48.78 million yuan, a decrease of 13.90% year-on-year[26] - The company's net profit for the period is projected to show significant changes compared to the same period last year, although specific figures are not disclosed[36] - Net profit for the period was CNY 48,391,484.27, a decline of 13.36% from CNY 55,770,916.88 in the same period last year[63] - The net profit for the current period is ¥44,080,297.75, a decline of 5.8% from ¥46,788,945.60 in the previous period[70] Cash Flow - Net cash flow from operating activities was -¥307,050,623.24, representing a decline of 138.53% compared to -¥128,727,834.88 in the previous year[8] - Net cash outflow from operating activities increased by 138.53% year-on-year, primarily due to increased cash payments related to operating activities[25] - The net cash flow from operating activities is negative at -¥307,050,623.24, worsening from -¥128,727,834.88 in the previous period[77] - The cash inflow from operating activities totaled ¥441,729,202.70, compared to ¥479,857,852.40 in the previous period[74] - The net cash flow from financing activities was $135,786,763.83, compared to a negative cash flow of $67,665,261.13 in the previous period, indicating a significant improvement[80] - The cash outflow for operating activities increased to $762,177,383.21 from $619,070,253.93, reflecting higher operational costs[81] - The company reported a cash flow from investment activities of -$18,113,171.42, an improvement from -$47,720,842.45 in the previous year[84] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,076,214,649.61, an increase of 3.39% from ¥3,942,592,048.87 at the end of the previous year[8] - The company's total assets amounted to CNY 4,076,214,649.61, an increase from CNY 3,942,592,048.87 at the end of 2019, representing a growth of approximately 3.4%[41] - Total liabilities increased to CNY 1,302,030,408.98 from CNY 1,220,317,707.40, representing a growth of about 6.7%[47] - The company's total liabilities stood at approximately $1.19 billion, reflecting ongoing financial obligations[88] - Total liabilities amounted to CNY 1,220,317,707.40, with total equity at CNY 2,722,274,341.47, resulting in total assets of CNY 3,942,592,048.87[91] - Current assets totaled CNY 2,526,499,869.01, while non-current assets were CNY 1,479,492,355.03, leading to a total asset figure of CNY 4,005,992,224.04[95] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 29,183[12] - The largest shareholder, Gao Shuhua, holds 35.69% of the shares, totaling 333,644,728 shares[12] - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[19] - The total equity attributable to shareholders increased to CNY 2,767,224,730.83 from CNY 2,714,925,009.49, reflecting a growth of approximately 1.9%[50] Operational Metrics - Operating costs decreased by 30.53% year-on-year, mainly due to reduced sales of heparin raw materials and low molecular weight heparin preparations[25] - The top five suppliers accounted for 38.18% of total purchases, amounting to 114.41 million yuan[28] - The top five customers accounted for 21.47% of total sales, amounting to 85.51 million yuan[28] - The company plans to continue expanding product varieties and improving product quality in line with its strategic goals[28] - The company reported a decrease in sales expenses to CNY 187,118,366.48, down from CNY 204,790,122.62[60] - Research and development expenses were CNY 23,722,505.21, slightly down from CNY 23,932,784.13[60] - Research and development expenses increased to ¥23,614,703.22, up from ¥22,737,595.31 in the previous period, indicating a focus on innovation[67] Inventory and Receivables - Cash and cash equivalents decreased by 32.65% compared to the beginning of the period, mainly due to the payment of deferred taxes from the previous year and increased raw material prices[24] - Accounts receivable financing decreased by 36.19% compared to the beginning of the period, primarily due to the endorsement transfer of high-credit bank acceptance bills[24] - Prepayments increased by 52.22% compared to the beginning of the period, mainly due to increased prepayments for raw material purchases and marketing expenses[24] - The company reported a decrease in accounts receivable to CNY 290,259,210.06 from CNY 296,770,247.07, a decline of about 2%[41] - The company holds cash and cash equivalents of CNY 534,684,295.86 and accounts receivable of CNY 297,427,381.25[91] - The company has a total of CNY 1,348,688,368.14 in inventory, reflecting its operational capacity[91] Financial Structure - The company's equity totaled CNY 2,785,446,657.23, an increase from CNY 2,741,366,359.48[57] - The total comprehensive income attributable to the parent company is ¥52,299,721.33, down from ¥58,802,105.75 in the previous period[66] - The company has no non-operating fund occupation by controlling shareholders or related parties during the reporting period[37] - The company has a retained earnings balance of CNY 1,184,663,530.00, indicating strong profitability retention[91] - The company has not undergone an audit for the first quarter report, which may affect the reliability of the financial data presented[98]